Logo image of ELUT

ELUTIA INC (ELUT) Stock Fundamental Analysis

NASDAQ:ELUT - Nasdaq - US05479K1060 - Common Stock - Currency: USD

3.22  +0.02 (+0.63%)

Fundamental Rating

1

Overall ELUT gets a fundamental rating of 1 out of 10. We evaluated ELUT against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of ELUT have multiple concerns. ELUT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ELUT has reported negative net income.
ELUT had a negative operating cash flow in the past year.
ELUT had negative earnings in each of the past 5 years.
In the past 5 years ELUT always reported negative operating cash flow.
ELUT Yearly Net Income VS EBIT VS OCF VS FCFELUT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

ELUT's Return On Assets of -149.14% is on the low side compared to the rest of the industry. ELUT is outperformed by 84.85% of its industry peers.
Industry RankSector Rank
ROA -149.14%
ROE N/A
ROIC N/A
ROA(3y)-57.16%
ROA(5y)-45.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELUT Yearly ROA, ROE, ROICELUT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

Looking at the Gross Margin, with a value of 42.42%, ELUT is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
In the last couple of years the Gross Margin of ELUT has grown nicely.
ELUT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.49%
GM growth 5Y1.8%
ELUT Yearly Profit, Operating, Gross MarginsELUT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

More info and screens

0

2. Health

2.1 Basic Checks

ELUT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ELUT has more shares outstanding
ELUT has more shares outstanding than it did 5 years ago.
ELUT has a worse debt/assets ratio than last year.
ELUT Yearly Shares OutstandingELUT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
ELUT Yearly Total Debt VS Total AssetsELUT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -7.02, we must say that ELUT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.02, ELUT is not doing good in the industry: 68.63% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.02
ROIC/WACCN/A
WACC9.85%
ELUT Yearly LT Debt VS Equity VS FCFELUT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

ELUT has a Current Ratio of 0.94. This is a bad value and indicates that ELUT is not financially healthy enough and could expect problems in meeting its short term obligations.
ELUT has a Current ratio of 0.94. This is amonst the worse of the industry: ELUT underperforms 89.13% of its industry peers.
A Quick Ratio of 0.85 indicates that ELUT may have some problems paying its short term obligations.
ELUT's Quick ratio of 0.85 is on the low side compared to the rest of the industry. ELUT is outperformed by 90.20% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.85
ELUT Yearly Current Assets VS Current LiabilitesELUT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ELUT have decreased strongly by -24.88% in the last year.
ELUT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.32%.
The Revenue has been decreasing by -8.72% on average over the past years.
EPS 1Y (TTM)-24.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.11%
Revenue 1Y (TTM)-25.32%
Revenue growth 3Y-16.61%
Revenue growth 5Y-8.72%
Sales Q2Q%-3.35%

3.2 Future

Based on estimates for the next years, ELUT will show a very strong growth in Earnings Per Share. The EPS will grow by 21.79% on average per year.
Based on estimates for the next years, ELUT will show a very strong growth in Revenue. The Revenue will grow by 24.99% on average per year.
EPS Next Y7.18%
EPS Next 2Y25.19%
EPS Next 3Y21.79%
EPS Next 5YN/A
Revenue Next Year-31.21%
Revenue Next 2Y-3.89%
Revenue Next 3Y24.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ELUT Yearly Revenue VS EstimatesELUT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
ELUT Yearly EPS VS EstimatesELUT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ELUT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELUT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELUT Price Earnings VS Forward Price EarningsELUT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELUT Per share dataELUT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ELUT's earnings are expected to grow with 21.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.19%
EPS Next 3Y21.79%

More info and screens

0

5. Dividend

5.1 Amount

ELUT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELUTIA INC

NASDAQ:ELUT (2/21/2025, 8:15:37 PM)

3.22

+0.02 (+0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners31.54%
Inst Owner ChangeN/A
Ins Owners2%
Ins Owner Change3.58%
Market Cap129.06M
Analysts82.5
Price Target9.18 (185.09%)
Short Float %0.26%
Short Ratio1.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-104.62%
Min EPS beat(2)-235.71%
Max EPS beat(2)26.47%
EPS beat(4)1
Avg EPS beat(4)-81%
Min EPS beat(4)-235.71%
Max EPS beat(4)26.47%
EPS beat(8)3
Avg EPS beat(8)-49.02%
EPS beat(12)4
Avg EPS beat(12)-36.11%
EPS beat(16)5
Avg EPS beat(16)-29.11%
Revenue beat(2)0
Avg Revenue beat(2)-9.64%
Min Revenue beat(2)-12.03%
Max Revenue beat(2)-7.25%
Revenue beat(4)1
Avg Revenue beat(4)-5.94%
Min Revenue beat(4)-12.06%
Max Revenue beat(4)7.59%
Revenue beat(8)2
Avg Revenue beat(8)-4.11%
Revenue beat(12)4
Avg Revenue beat(12)-2.23%
Revenue beat(16)6
Avg Revenue beat(16)-0.73%
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)-2.04%
EPS NQ rev (3m)41.18%
EPS NY rev (1m)-2.67%
EPS NY rev (3m)26.72%
Revenue NQ rev (1m)-7.81%
Revenue NQ rev (3m)-14.49%
Revenue NY rev (1m)-1.98%
Revenue NY rev (3m)-6.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.1
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.61
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.79
BVpS-1
TBVpS-1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -149.14%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.42%
FCFM N/A
ROA(3y)-57.16%
ROA(5y)-45.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.49%
GM growth 5Y1.8%
F-Score3
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.57%
Cap/Sales 1.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.94
Quick Ratio 0.85
Altman-Z -7.02
F-Score3
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)11.21%
Cap/Depr(5y)13.05%
Cap/Sales(3y)1.09%
Cap/Sales(5y)1.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.11%
EPS Next Y7.18%
EPS Next 2Y25.19%
EPS Next 3Y21.79%
EPS Next 5YN/A
Revenue 1Y (TTM)-25.32%
Revenue growth 3Y-16.61%
Revenue growth 5Y-8.72%
Sales Q2Q%-3.35%
Revenue Next Year-31.21%
Revenue Next 2Y-3.89%
Revenue Next 3Y24.99%
Revenue Next 5YN/A
EBIT growth 1Y-46.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.72%
OCF growth 3YN/A
OCF growth 5YN/A